Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin for Insulin Sensitivity and Liver Fat
NCT02290106Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Pitavastatin with Placebo (2 arms). Primary endpoints: Insulin-stimulated Glucose Uptake at 6 months and Liver Fat at 6 months. Started Mar 2015; status: completed.
02
Drugs
pitavastatin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02290106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02290106.